drug discovery

Hsiri Therapeutics is focused on discovering and developing therapies for infections due to drug resistant bacteria and drug resistant fungal diseases. Its research focuses on mycobacterial infections, resistant bacterial pathogens, and drug resistant fungal pathogens. Research concepts originated from the University of Notre Dame and Montana State University. Discovery and research laboratories are located in South Bend, IN, with corporate and development staff in Media, PA.

antimicrobial researchrational drug designresearch and development

iNFixion Bioscience is a drug discovery company dedicated to developing drugs that treat and prevent the clinical manifestations of neurofibromatosis type 1 (NF1) for all patients, regardless of their specific genetic mutation. Its approach addresses the lack of functional NF1 protein (neurofibromin) by enhancing the body's ability to produce and maintain healthy neurofibromin, aiming to create a disease-modifying therapy that alleviates symptoms and prevents disease progression.

drug development

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel cancer therapies. Its core technology leverages inhibition of nuclear export (XPO1 inhibition) and it describes itself as the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology.

commercializationdrug developmentSINE technologyXPO1 inhibition

Khloris Biosciences, Inc. is a biotechnology company based in San Jose, California, dedicated to revolutionizing the medical treatment and prevention of cancer and other diseases by harnessing the immunotherapeutic potential of induced pluripotent stem cells (iPSCs) for drug discovery, vaccine and cell therapies. It states it is the first and only company to develop cancer vaccines using patient-derived iPSCs and a leader in using iPSC-derived cardiomyocytes for the treatment of cardiovascular diseases.

cell therapiesiPSC-based vaccine development

Kura Oncology, Inc. is a biopharmaceutical company that discovers and develops novel cancer therapeutics, aiming to realize the promise of precision medicines to help patients with cancer lead better, longer lives. Its therapies are designed to selectively target cancer cells, and it investigates them in combination with standards of care. It focuses on areas including head and neck cancer, lung cancer and acute leukemias.

clinical developmentdrug developmentprecision oncology

Kyowa Kirin is a Japan-based global specialty pharmaceutical company that contributes to human health and well-being worldwide through innovative drug discovery and global commercialization. Driven by state-of-the-art antibody technologies, it focuses on core therapeutic areas of oncology, nephrology, central nervous system and immunology, as well as bone & mineral diseases, hematological diseases and rare diseases.

antibody technologiesglobal commercializationhematopoietic stem cell gene therapy (HSC-GT)open innovation and partnershipsproduction and quality assurance